5002 Photosystem II reaction centre subunit H, transmembrane region
Ligands and drugs
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.
The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.
| Superclass | Proteins | Expected | 0.25×observed / expected4× | Ratio | Significance |
|---|---|---|---|---|---|
| Homogeneous metal compounds | 0 | 8.2 | 0 | q < 0.0001 | |
| Hydrocarbons | 3 | 0.1 | 26× | not tested | |
| Lipids and lipid-like molecules | 17 | 1.9 | 9.11× | not tested | |
| Organoheterocyclic compounds | 2 | 2.6 | 0.78× | not tested | |
| Organic acids and derivatives | 1 | 2.6 | 0.39× | not tested | |
| Organic oxygen compounds | 1 | 3.3 | 0.30× | not tested | |
| Homogeneous non-metal compounds | 1 | 3.6 | 0.28× | not tested |
Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB03429 | CDL | Tetrastearoyl cardiolipin | 82 |
| DB04079 | HTO | Heptane-1,2,3-Triol | 15 |
| DB09270 | U10 | Ubidecarenone | 11 |
| DB01728 | PEF | 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine | 8 |
| DB13075 | MQ7 | Menaquinone 7 | 4 |
| DB01853 | BCL | Bacteriochlorophyll A | 2 |
| DB03152 | BGL | B-2-Octylglucoside | 1 |
| DB04464 | FME | N-Formylmethionine | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| CDL | CARDIOLIPIN | 101 |
| PGV | (1R)-2-{[{[(2S)-2,3-DIHYDROXYPROPYL]OXY}(HYDROXY)PHOSPHORYL]OXY}-1-[(PALMITOYLOXY)METHYL]ETHYL (11E)-OCTADEC-11-ENOATE | 21 |
| HTO | HEPTANE-1,2,3-TRIOL | 14 |
| PC1 | 1,2-DIACYL-SN-GLYCERO-3-PHOSPHOCHOLINE | 12 |
| PEF | DI-PALMITOYL-3-SN-PHOSPHATIDYLETHANOLAMINE | 10 |
| UNL | Unknown ligand | 10 |
| CD4 | (2R,5R,11R,14R)-5,8,11-trihydroxy-5,11-dioxido-17-oxo-2,14-bis(tetradecanoyloxy)-4,6,10,12,16-pentaoxa-5,11-diphosphatriacont-1-yl tetradecanoate | 8 |
| NKP | (2R)-2-hydroxy-3-(phosphonooxy)propyl (9E)-octadec-9-enoate | 7 |
| GGD | NONADEC-10-ENOIC ACID2-[3,4-DIHYDROXY-6-HYDROXYMETHYL-5-(3,4,5-TRIHYDROXY-6-HYDROXYMETHYL-TETRAHYDRO-PYRAN-2-YLOXY)-TETRAHYDRO-PYRAN-2-YLOXY]-1-OCTADEC-9-ENOYLOXYMETHYL-ETHYL ESTER | 6 |
| PGW | (1R)-2-{[(S)-{[(2S)-2,3-dihydroxypropyl]oxy}(hydroxy)phosphoryl]oxy}-1-[(hexadecanoyloxy)methyl]ethyl(9Z)-octadec-9-enoate | 6 |
| 3PE | 1,2-Distearoyl-sn-glycerophosphoethanolamine | 5 |
| 0V9 | (19R,22S)-25-amino-22-hydroxy-22-oxido-16-oxo-17,21,23-trioxa-22lambda~5~-phosphapentacosan-19-yl (9Z)-hexadec-9-enoate | 4 |
| MW9 | (21R,24R,27S)-24,27,28-trihydroxy-18,24-dioxo-19,23,25-trioxa-24lambda~5~-phosphaoctacosan-21-yl (9Z)-octadec-9-enoate | 4 |
| OTP | (2E,6E,10E,14E,18E,22E,26E)-3,7,11,15,19,23,27,31-OCTAMETHYLDOTRIACONTA-2,6,10,14,18,22,26,30-OCTAENYL TRIHYDROGEN DIPHOSPHATE | 4 |
| V7B | [(2~{S})-3-[(2~{R},3~{R},4~{R},5~{S},6~{R})-6-(hydroxymethyl)-5-[(2~{R},3~{R},4~{S},5~{S},6~{R})-6-(hydroxymethyl)-3,4,5-tris(oxidanyl)oxan-2-yl]oxy-3,4-bis(oxidanyl)oxan-2-yl]oxy-2-(12-methyltridecanoyloxy)propyl] 12-methyltridecanoate | 4 |
| 8K6 | Octadecane | 3 |
| CL | CHLORIDE ION | 3 |
| PTY | PHOSPHATIDYLETHANOLAMINE | 3 |
| 07D | Trans-Geranyl BACTERIOCHLOROPHYLL A | 2 |
| 6PL | (4S,7R)-4-HYDROXY-N,N,N-TRIMETHYL-9-OXO-7-[(PALMITOYLOXY)METHYL]-3,5,8-TRIOXA-4-PHOSPHAHEXACOSAN-1-AMINIUM 4-OXIDE | 2 |